ペントキシフィリンは,ドクソルビシンとブレオミシンのアポトーシス,カスパース活性,細胞サイクルに対する効果を高め,ホジキン病の細胞系における増殖と衰老を減少させます.
PubMedで要約を見る
まとめ
この要約は機械生成です。ペントキシフィリン (PTX) は,がん細胞死亡を誘導し,副作用を軽減することによって,ホジキンリンパ腫 (HL) の化学療法を強化します. この研究は,PTXがアポトーシスを促進し,HL細胞の治療抵抗性を克服することを示しています.
科学分野
- 腫瘍学
- 薬理学について
- 癌 生物学
背景
- ホッジキンリンパ腫 (HL) のドクソルビシン (DOX) とブレオミシン (BLM) の治療は,特に進行した段階で制限があります.
- 現在の治療法による重篤な副作用は 新しい治療戦略を必要とします
- ペントキシフィリン (PTX) は,NF- kB阻害剤であり,化学療法の有効性を高める可能性を示しています.
研究 の 目的
- HL細胞に対するPTX単独およびDOXおよびBLMとの組み合わせの効果を評価する.
- HLにおけるアポトーシス,増殖,老化,重要な分子経路に対するPTXの影響を評価する.
主な方法
- Hs-445 HL細胞はPTX,DOX,BLMで処理されました.
- 細胞活性,アポトーシス,カスパース活性,細胞サイクル,ミトコンドリア膜ポテンシャル (ΔΨm),増殖,クローノジェニシティ,遺伝子発現 (qPCR) を含む.
- 分析にはフローサイトメトリーとスペクトロフォトメトリーを使用した.
主要な成果
- PTXは,特に併用療法では,HL細胞におけるアポトーシスを有意に誘発した.
- PTXが遺伝子発現を調節し,プロアポプトシスマーカーを増加させ,アンチアポプトシスマーカーを減少させた.
- PTXはカスパース活性を増強し,ΔΨmを阻害し,増殖/クローノゲニシティを減少させ,DOX/BLM誘発の衰老を逆転させた.
結論
- PTXはHL細胞に強力なアポトーシス誘発効果を示しています.
- PTXは DOXとBLMの細胞毒性を相乗的に強化する.
- PTXはホジキンリンパ腫の補助療法として有望であり,副作用を軽減し,治療結果を改善する可能性がある.
関連する概念動画
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...

